Crossmark

Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2021: an observational study from the French national health data system

Crossref DOI link: https://doi.org/10.1007/s10198-025-01864-6

Published Online: 2025-11-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chouaid, Christos

Marchal, Clarisse

Apert, Marion

Bensimon, Lionel

Guimard, Valérie

Née, Mélanie

Belhassen, Manon https://orcid.org/0000-0002-9478-5464
de Pouvourville, Gérard

Blay, Jean-Yves
Funding

Funding for this research was provided by:

Merck Sharp and Dohme France (Merck Sharp and Dohme France)
License Information

Text and Data Mining valid from 2025-11-12

Version of Record valid from 2025-11-12
More Information

Article History

Received: 21 October 2024

Accepted: 17 October 2025

First Online: 12 November 2025

Declarations

:

: CC reports personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen et Amgen. CM, MN and MB are full time employees of PELyon. MA, LB and VG are full time employees of MSD. GdP reports personal fees from MSD as member of the Scientific Committee of the ELO study since 2020. JYB reports research grants from Roche, AstraZeneca, MSD, BMS and GSK.

Document is current

Any future updates will be listed below